1-10 of 10
John F. Seymour
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

Open Access
Nitin Jain, Lisa J. Croner, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Xavier C. Badoux, Karl Eckert, Leo W.K. Cheung, Anwesha Mukherjee, James P. Dean, Edith Szafer-Glusman, John F. Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 498–505.
https://doi.org/10.1158/1078-0432.CCR-22-3934
Published: 01 February 2024
View articletitled, Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Open the PDF for Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax in another window
Includes: Supplementary data
Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Available to Purchase
Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 603–608.
https://doi.org/10.1158/1078-0432.CCR-21-1237
Published: 15 February 2022
View articletitled, Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Open the PDF for Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare) in another window
Journal Articles

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Open Access
Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre, William G. Wierda, Abhijeet Kumar, Thomas J. Kipps, Michelle Boyer, Ahmed Hamed Salem, John C. Pesko, Jennifer A. Arzt, Margaret Mantas, Su Y. Kim, John F. Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4690–4695.
https://doi.org/10.1158/1078-0432.CCR-20-4842
Published: 01 September 2021
View articletitled, Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Open the PDF for Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study in another window
Includes: Supplementary data
Journal Articles

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Free
Matthew S. Davids, Michael Hallek, William Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E. Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F. Seymour
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4371–4379.
https://doi.org/10.1158/1078-0432.CCR-17-3761
Published: 14 September 2018
View articletitled, Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Open the PDF for Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

Free
Anastasios Stathis, Alexia Iasonos, John F. Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 2993–2998.
https://doi.org/10.1158/1078-0432.CCR-17-3021
Published: 01 July 2018
View articletitled, Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Open the PDF for Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas in another window
Journal Articles

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

Free
Andrew W. Roberts, Stephan Stilgenbauer, John F. Seymour, David C.S. Huang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (16): 4527–4533.
https://doi.org/10.1158/1078-0432.CCR-16-0955
Published: 14 August 2017
View articletitled, Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
Open the PDF for Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia in another window
Journal Articles

BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

Free
Susan Branford, John F. Seymour, Andrew Grigg, Chris Arthur, Zbigniew Rudzki, Kevin Lynch, Timothy Hughes
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7080–7085.
https://doi.org/10.1158/1078-0432.CCR-07-0844
Published: 03 December 2007
View articletitled, BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
Open the PDF for BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria in another window
Journal Articles

Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma

Free
Maher K. Gandhi, Eleanore Lambley, Jacqueline Burrows, Ujjwal Dua, Suzanne Elliott, Peter J. Shaw, H. Miles Prince, Max Wolf, Kerrie Clarke, Craig Underhill, Tony Mills, Peter Mollee, Devinder Gill, Paula Marlton, John F. Seymour, Rajiv Khanna
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 460–464.
https://doi.org/10.1158/1078-0432.CCR-05-2008
Published: 20 January 2006
View articletitled, Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma
Open the PDF for Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma in another window
Journal Articles

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

Free
H Miles Prince, Linda Mileshkin, Andrew Roberts, Vinod Ganju, Craig Underhill, John Catalano, Richard Bell, John F. Seymour, David Westerman, Paul J. Simmons, Kate Lillie, Alvin D. Milner, Juliana Di Iulio, Jerome B. Zeldis, Robert Ramsay
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5504–5514.
https://doi.org/10.1158/1078-0432.CCR-05-0213
Published: 01 August 2005
View articletitled, A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Open the PDF for A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

Confirmation of the Activity of the Interleukin-2 Fusion Toxin Denileukin Diftitox against Chemorefractory Chronic Lymphocytic Leukemia, including Cases with Chromosome 17p Deletions and without Detectable CD25 Expression

Free
Susan J. Morgan, John F. Seymour, H. Miles Prince, David A. Westerman, Max M. Wolf
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3572–3575.
https://doi.org/10.1158/1078-0432.3572.10.10
Published: 24 May 2004
View articletitled, Confirmation of the Activity of the Interleukin-2 Fusion Toxin Denileukin Diftitox against Chemorefractory Chronic Lymphocytic Leukemia, including Cases with Chromosome 17p Deletions and without Detectable CD25 Expression
Open the PDF for Confirmation of the Activity of the Interleukin-2 Fusion Toxin Denileukin Diftitox against Chemorefractory Chronic Lymphocytic Leukemia, including Cases with Chromosome 17p Deletions and without Detectable CD25 Expression in another window